Pfizer reported fourth-quarter earnings of 42 cents per share, below the 50 cents expected by consensus while revenue was 11.7 billion, slightly above expectations of 11.5 billion. The pharmaceutical group, however, surprised the market by indicating that it is witnessing that sales of the anti-covid vaccine produced together with the German BioNTech will generate sales of 15 billion dollars in the 2021 while consensus expectations were steady at 12.7.